X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, Avance Clinical will manage the Phase 1 clinical trial of EB-373 in coordination with Enveric. EB-373 is designed as a next-generation proprietary psilocin prodrug and developed leveraging its Psybrary™ drug discovery platform to target anxiety disorders.
Lead Product(s): EB-373
Therapeutic Area: Psychiatry/Psychology Product Name: EB-373
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Enveric Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 23, 2023
Details:
No severe adverse events were noted as PRV-002 was well-tolerated for all cohorts. No delays were instituted between cohorts. Vital signs, EKG readings, sleep patterns and breathing function were all normal through the entirety of the study.
Lead Product(s): PRV-002
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: PRV-002
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Odyssey Health
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2022
Details:
The study is a double-blinded, randomized, and placebo-controlled safety study of AT-301 nasal spray in 32 healthy adult subjects divided into two study groups.
Lead Product(s): AT-301
Therapeutic Area: Infections and Infectious Diseases Product Name: AT-301
Highest Development Status: PreclinicalProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Atossa Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 22, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
